| |
| Advisory Council |
| OUR ADVISORS |
 |
|
David Dornsife
Chairman and CEO, Herrick Corporation |
Dave Dornsife is Chairman of the Board of the Herrick Corporation
(and its subsidiaries), a Pleasanton, California based steel fabrication and installation company, and of the Gilllig Corporation, a Hayward, California based bus manufacturing company that is a major supplier
of metropolitan transit vehicles. He is a 1965 graduate of the USC Marshall School of Business, where he is now a trustee and serves on |
|
| the Board of Directors for the Brain and Creativity Institute through the College of Letters, Arts and Sciences. Dave is also a trustee of the San Francisco Theological Seminary. |
|
| Dave is Vice President of the Hedco Foundation, whose mission is health and educational improvement. Hedco has sponsored many programs worldwide. Dave and his wife, Dana, support World Vision, an international humanitarian agency. Through World Vision in West Africa, they maintain micro-enterprise, agriculture and literacy programs in the Islamic Republic of Mauritania, and water-well drilling in Mali, Niger, Ghana and Ethiopia, in partnership with The Conrad N. Hilton Foundation. They support a medical clinic in Roatan, Honduras through Global Healing, an organization dedicated to providing modern healthcare in developing countries. Dave serves as a council member for the Yosemite Fund and was recently inducted into the Phi Kappa Phi Honor Society at USC for meritorious service. |
 |
|
Erlinda M. Gordon, M.D.
Vice President, Operations and Medical Affairs
Epeius Biotechnologies
|
| Prior to founding Epeius Biotechnologies, Dr. Gordon held the following positions at the Keck School of Medicine at the University of Southern California: Associate Professor of Pediatrics, Medical Director of the Vector Production Unit, and Director of the Molecular Therapeutics Division of the Gene Therapy Laboratories. |
|
|
Her long-standing contributions to cancer research began with her work on the novel cancer drug VM26, for treatment of acute monoblastic leukemia in infants (published in Blood, the official journal of the American Society of Hemotology, 1984). Dr. Gordon is recognized for her original research and extensive publication history in the field of gene therapy. She was recipient of a Research Career Development Award from the National Institutes of Health (NIH), and has extensive experience in Phase I–IV NIH-sponsored clinical trials for pediatric cancer (Childrens Cancer Study Group) and hemophilia. Dr. Gordon is the Federal Drug Administration (FDA) liaison and Gene Therapy Sponsor for
a Phase I clinical trial for metastatic colorectal cancer in the United States, and a Phase I/II clinical trial for advanced pancreatic cancer and other solid tumors in the Philippines, using the Epeius’ targeted injectable vector for gene delivery to cancerous lesions. |
|
| Dr. Gordon is a board certified pediatric hematologist-oncologist and received her M.D. degree (cum laude) in 1971 from the University of Santo Tomas School of Medicine and Surgery in Manila, Philippines. She completed her pediatric residency and hematology- oncology fellowship training at Case Western Reserve University School of Medicine in Cleveland, Ohio. |
 |
|
Frederick L. Hall, Ph.D.
Founder, President and Chief Executive Officer,
Epeius Biotechnologies |
Prior to founding Epeius Biotechnologies, Dr. Hall served for twelve years at the University of Southern California School of Medicine
as Director of Research in the Departments of Orthopedic Surgery, Cardiothoracic Surgery, and Colorectal Surgery, and as an Associate Professor of Molecular Pharmacology and Toxicology at the USC School of Pharmacy. |
|
His research focused on the biochemistry of protein phosphorylation: the study of regulatory enzymes that govern the molecular mechanisms of growth factor action
and cell cycle control. His laboratory is credited with the biochemical characterization
of an important family of protein kinases and the molecular cloning of several critical
cell cycle control genes, including the human CAK1, MAT1, and Cyclin G1 genes, the latter of which represents a critical proto-oncogene that is over-expressed in numerous cancer cells.
|
In collaboration with Dr. Erlinda Gordon, Dr. Hall developed a series of proprietary
cyclin G1 knockout constructs that were shown to be effective as cytocidal gene
therapy vectors for cancer. To enable the advancement of these gene therapy vectors
into clinical applications, Dr. Hall and Dr. Gordon subsequently developed the targeted injectable retroviral vector platform technology (TDS technology) that serves as the
basis for Epeius' proprietary targeted therapeutics. |
|
|
